Latest News

New Publication (2016)

Kawasaki Disease: Current Understanding of the Mechanism and Evidence-Based Treatment, 1st ed. 2017 Edition  (Informational flyer:  KDbook_Saji2016_flyer.pdf )


Published KD articles


  1. 2014 Lancet:  Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
  2. (Adult KD) 2017 Global CardiologyManagement of sequelae of Kawasaki     (Portuguese translation)

Possible cause of Kawasaki disease found

More information about possible cause and source of Kawasaki disease found, and published by the press release from UCSD.

2018 Kawasaki Disease Parent Symposium

Thank you to all who attended the 2018 KD Parent Symposium last September 29, 2018 and to the KD Foundation for sponsoring the event.  If you were unable to attend in person or participate in the live event on Facebook, you may view the videos using the links below.


* Eczema and KD: There is a link between eczema, a genetic condition, and KD which has a genetic basis for susceptibility. It is very common to see eczema in KD patients. 
* KD and African American children: The genetic susceptibility is higher in African Americans more than Caucasian and Latinos in the US. More research is needed to understand the overrepresentation of African Americans in KD. 
* CT Calcium Score: The UCSD team is only recommending the score for patients who have had dilation or aneurysms of the coronary artery or for whom the results of the initial echo is unknown.
* Vaccines and KD: Panels have been appointed by the vaccine companies to adjudicate relationship between a vaccine and subsequent KD and the expert panels found no relationship. The CDC has also published a paper looking at KD/vaccine relationships, and none was found.

SAVE THE DATE:  2019 Kawasaki Disease Parent Symposium 

Date:        Saturday, October 19, 2019

Time:         9:00 AM - 12:00 PM

Venue:      Telemedicine Building Auditorium, UC San Diego, 9500 Gilman Dr, La Jolla, CA 92093

Contact:  Email  to join the KD mailing list.